Bleeding and thrombotic complications in critically ill patients with cancer

Critical Care Clinics

Volumn 17, Issue 3, 2001, Pages 599-622

  DeSancho, Maria T ^b   Rand, Jacob H ^b  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR; ERYTHROPOIETIN; HEPARIN; RECOMBINANT BLOOD CLOTTING FACTOR 7A; VON WILLEBRAND FACTOR;

BLEEDING; CANCER PATIENT; CENTRAL VEIN; DIAGNOSTIC IMAGING; DIFFERENTIAL DIAGNOSIS; DISSEMINATED INTRAVASCULAR CLOTTING; HEMOSTASIS; HUMAN; INDWELLING CATHETER; INTENSIVE CARE UNIT; PATHOPHYSIOLOGY; PATIENT CARE; PRIORITY JOURNAL; REVIEW; THROMBOCYTE ANOMALY; THROMBOCYTOPENIA; THROMBOSIS; UREMIA;

EID: 0034883419     PISSN: 07490704     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0749-0704(05)70200-1     Document Type: Article

References (151)

1. Treatment of venous thromboembolism
2. Clinical uses of low-molecular-weight heparins
3. Platelet factor 4 complexed to heparin is the target for antibodies generated in heparin-induced thrombocytopenia
4. Microangiopathic hemolytic anemia and cancer: A review
5. Thrombosis and cancer
6. Haemostasis in malignant disease
7. Venous thromboembolism and cancer
8. Acute complications of central line placement in profoundly thrombocytopenic cancer patients
9. Treatment of venous thromboembolism
10. Nonbacterial thrombotic endocarditis in cancer patients: Comparison of characteristics of patients with and without concomitant disseminated intravascular coagulation
11. Very low doses of warfarin can prevent thrombosis in central venous catheters. A randomized prospective trial
12. D-dimer testing as an adjunct to ultrasonography in patients with clinically suspected deep vein thrombosis: Prospective cohort study
13. The effects of standard and low molecular weight heparin on bone nodule formation in vitro
14. Coagulation abnormalities in malignancy: A review
15. Thrombotic complications of central venous catheters in cancer patients
16. Efficacy and safety of oral anticoagulation in patients with cancer
17. The efficacy and safety of oral anticoagulation in patients with cancer
18. Respiratory dysfunction in thrombotic thrombocytopenic purpura
19. Prevention of central venous catheter associated thrombosis using minidose warfarin in patients with haematological malignancies
20. Thrombotic microangiopathic syndromes after bone marrow transplantation
21. A randomized trial of anticoagulation with warfarin and of alternating chemotherapy in extensive small-cell lung cancer by the Cancer and Leukemia Group B
22. Strategies for the diagnosis of deep vein thrombosis and pulmonary embolism
23. Disseminated intravascular coagulation due to malignancy
24. Consensus conference on platelet transfusion. Final statement
25. Comparative studies of blood coagulation and platelet aggregation in patients with cancer and nonmalignant diseases
26. A clinical trial of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis
27. Cerebrovascular accidents in infective endocarditis: Role of anticoagulation
28. Practice parameter for the use of flesh-frozen plasma, cryoprecipitate, and platelets. Fresh-Frozen Plasma, Cryoprecipitate, and Platelets Administration Practice Guidelines
29. In vivo thrombin and plasmin activities in patients with acute promyelocytic leukemia (APL): Effect of all-trans retinoic acid (ATRA) therapy
30. Coagulation disorders associated with acute promyelocytic leukemia: Corrective effect of all-trans retinoic acid treatment
31. Thrombocytopenic disorders in critically ill patients
32. Venous thromboembolism in the cancer patient
33. Cardiac valvular vegetations in cancer patients: A prospective echocardiographic study of 200 patients
34. First workshop for detection of heparin-induced antibodies: Validation of the heparin-induced platelet-activation test (HIPA) in comparison with a PF4/heparin ELISA
35. Haemolytic uraemic syndrome in a patient with lung cancer: Further evidence for a toxic interaction between mitomycin-C and tamoxifen
36. Management of oral anticoagulant therapy. Experience with an anticoagulation clinic
37. Mechanisms of hypercoagulation in malignancy and during chemotherapy
38. Differential regulation of platelet aggregation by matrix metalloproteinases-9 and -2
39. Risk factors for complications of chronic anticoagulation. A multicenter study
40. Hemostasis and malignancy
41. Von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome
42. Prevention of post-operative deep leg vein thrombosis in patients with cancer
43. Arterial thrombosis after treatment with bleomycin and cisplatin
44. Management of venous thromboembolism
45. The use of D-dimer testing and impedance plethysmographic examination in patients with clinical indications of deep vein thrombosis
46. Sensitivity and specificity of a rapid whole-blood assay for D-dimer in the diagnosis of pulmonary embolism
47. Bleeding and thromboembolism during anticoagulant therapy: A population-based study in Rochester, Minnesota
48. Safety of stringent prophylactic platelet transfusion policy for patients with acute leukaemia
49. Coagulation disorders in cancer
50. Thrombolytic therapy in venous thromboembolism. Clinical trials and current indications
51. Cancer- and drug-associated thrombotic thrombocytopenic purpura and hemolytic uremic syndrome
52. Cerebrovascular complications in patients with cancer
53. Lower mortality in cancer patients treated with low-molecular-weight versus standard heparin
54. A survey of 215 non-hemophilic patients with inhibitors to factor VIII
55. Annexin II: A novel mediator of cell surface plasmin generation
56. Characterization of the platelet-aggregating activity of tumor cells
57. Platelets as a source of growth-promoting factor(s) for tumor cells
58. Changes in the natural anticoagulants following bone marrow transplantation
59. Solid tumors and factor VIII antibodies
60. Randomized study of prophylactic platelet transfusion threshold during induction therapy for adult acute leukemia: 10,000/microL versus 20,000/microL
61. Recombinant activated factor VII as a universal haemostatic agent
62. NovoSeven as a universal haemostatic agent
63. Inhibition of metastases by anticoagulants
64. Coagulation patterns of disseminated intravascular coagulation in acute promyelocytic leukemia
65. Oral anticoagulants: Mechanism of action, clinical effectiveness, and optimal therapeutic range
66. Antithrombin III profiles in malignancy, relationship primary tumors and metastatic sites
67. Subcutaneous low-molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis
68. Heparm for 5 days as compared with 10 days in the initial treatment of proximal venous thrombosis
69. Venous thromboembolism
70. Antithrombotic therapy for venous thromboembolic disease
71. Treatment of patients with venous thromboembolism and malignant disease: Should vena cava filter placement be routine?
72. Bleeding, clotting and cancer
73. Acute promyelocytic leukemia. M.D. Anderson Hospital experience
74. Initial treatment of venous thromboembolism
75. The role of venous ultrasonography in the diagnosis of suspected deep venous thrombosis and pulmonary embolism
76. Noninvasive diagnosis of deep venous thrombosis. McMaster Diagnostic Imaging Practice Guidelines Initiative
77. The clinical management of heparin-induced thrombocytopenia
78. Nonbacterial thrombotic endocarditis (NBTE) and disseminated intravascular coagulation (DIC): Autopsy study of 36 patients
79. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home
80. The use of thrombus precursor protein, D-dimer, prothrombin fragment 1.2, and thrombin antithrombin in the exclusion of proximal deep vein thrombosis and pulmonary embolism
81. Anticoagulant-related bleeding: Clinical epidemiology, prediction, and prevention
82. Clinical utility of a rapid whole-blood D-dimer assay in patients with cancer who present with suspected acute deep venous thrombosis
83. Treatment of deep venous thrombosis with low-molecular-weight heparins. A meta-analysis
84. Disseminated intravascular coagulation
85. A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis
86. The thrombogenic effect of anticancer drug therapy in women with stage II breast cancer
87. Hemorrhagic complications of anticoagulant treatment
88. Anticoagulation with Novastan (argatroban) in patients with heparin-induced thrombocytopenia and heparin-induced thrombocyto penia and thrombosis syndrome
89. Mechanisms of hemorrhage in leukemias
90. Microangiopathic hemolytic anemia in metastatic carcinoma. Report of eight cases
91. Acute arterial thrombosis in a patient with small cell lung cancer after a cycle of chemotherapy with cisplatin and etoposide
92. Hemostatic drugs
93. Thrombotic thrombocytopenic purpura seen as pulmonary hemorrhage
94. Randomized trial of chemotherapy and radiation therapy with or without warfarin for limited-stage small-cell lung cancer: A Cancer and Leukemia Group B study
95. Annexin II and bleeding in acute promyelocytic leukemia
96. Coagulation disorders in cancer. I. Clinical and laboratory studies
97. Thrombotic thrombocytopenic purpura today
98. Arterial thrombosis after chemotherapy with cisplatin, vinblastine and methotrexate
99. A toxic interaction between mitomycin C and tamoxifen causing the haemolytic uraemic syndrome
100. Anticoagulants, venous thromboembolism, and the cancer patient
101. Decreased tissue factor and tissue-plasminogen activator antigen in relapsed acute promyelocytic leukemia
102. Hemostatic abnormalities in untreated cancer: Incidence and correlation with thrombotic and hemorrhagic complications
103. Hemostasis in malignancy
104. Platelet contribution to cancer cell growth and migration: The role of platelet growth factors
105. Antithrombotic strategies in patients with cancer
106. Comparison of subcutaneous low-molecular-weight heparin with intravenous standard heparin in proximal deep-vein thrombosis
107. The long-term clinical course of acute deep venous thrombosis
108. Venous thromboembolism and cancer
109. The weight-based heparin dosing nomogram compared with a "standard care" nomogram. A randomized controlled trial
110. Thrombosis, markers of thrombotic risk, indwelling central venous catheters and antithrombotic prophylaxis using low-dose warfarin in subjects with malignant disease
111. The threshold for prophylactic platelet transfusions in adults with acute myeloid leukemia
112. Activation of blood coagulation in cancer: Trousseau's syndrome revisited
113. Abnormalities of blood coagulation in patients with cancer. Fibrinopeptide A generation and tumor growth
114. Hemostatic alterations in cancer patients
115. Prevention of postoperative deep vein thrombosis in patients with malignant disease
116. Clotting activation and impairment of fibrinolysis in malignancy
117. Mucinous malignancies, venous thrombosis and terminal endocarditis with emboli. A syndrome
118. Vascular-bed-specific hemostasis and hypercoagulable states
119. Trousseau's syndrome and other manifestations of chronic disseminated coagulopathy in patients with neoplasms: Clinical, pathophysiologic, and therapeutic features
120. Antibodies against factor VIII in patients with solid tumors: Successful treatment of cancer may suppress inhibitor formation
121. Diagnosis and treatment of cancer-related thrombosis
122. Malignancy-associated microangiopathic hemolytic anemia
123. Arterial thrombosis in a patient after chemotherapy (BEP protocol) for extra-gonadal dysgerminoma
124. Incidence of cancer after prophylaxis with warfarin against recurrent venous thromboembolism. Duration of Anticoagulation Trial
125. Hemorrhagic and thrombotic abnormalities of cancer
126. A comparison of low-molecular-weight heparin with unfractionated heparin for acute pulmonary embolism
127. Low-molecular-weight heparins and unfractionated heparin in the treatment of patients with acute venous thromboembolism: Results of a meta-analysis
128. Platelet transfusions a constantly evolving therapy
129. Hemostasis in malignancy
130. The risk of a diagnosis of cancer after primary deep venous thrombosis or pulmonary embolism
131. Hemostatic abnormalities in malignancy, a prospective study of one hundred eight patients. Part I. Coagulation studies
132. Enhanced expression of urokinase receptor induced through the tissue factor-factor VIIIa pathway in human pancreatic cancer
133. Low-molecular-weight heparin in the treatment of patients with venous thromboembolism
134. Haemolytic uraemic syndrome following bone marrow transplantation. Case report and review of the literature
135. Acquired von Willebrand syndrome: From pathophysiology to management
136. Metastatic cancer. A relative contraindication to vena cava filter placement
137. Heparin-induced thrombocytopenia. Pathogenesis, frequency, avoidance and management
138. Heparin-induced thrombocytopenia: A ten-year retrospective
139. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin
140. Low-molecular-weight heparins
141. Value of assessment of pretest probability of deep-vein thrombosis in clinical management
142. Accuracy of clinical assessment of deep-vein thrombosis
143. The fibrinolytic enzyme system. Basic principles and links to venous and arterial thrombosis
144. Transfusion and stem cell support in cancer treatment
145. Fibrinopeptide A (FPA) level and fibrinogen kinetics in patients with malignant disease
146. Effect of warfarin on survival in small cell carcinoma of the lung. Veterans Administration Study No. 75
147. Occurrence of fibrin and tissue factor antigen in human small cell carcinoma of the lung
148. Warfarin for cancer prevention
149. Gastric carcinoma and thrombotic thrombocytopenic purpura: Association with plasma immune complex concentrations